No Data
No Data
No Data
No Data
No Data
Hebo Pharmaceutical-B (02142) issued 98,000 shares under the share award program on April 18
Heplatinum Pharmaceutical-B (02142) issued an announcement on April 18, 2024, according to November 2, 2020...
Zhitong FinanceApr 18 06:31 ET
Wang Jingsong, chairman of the board of directors of Harbour BioMed (02142), promised not to reduce the company's shares for at least six months
Harbour BioMed (02142) announced that Dr. Wang Jingsong, Executive Director, Chief Executive Officer and Chairman of the Board of Directors, has voluntarily promised...
Zhitong FinanceApr 17 04:31 ET
Market Cool On HBM Holdings Limited's (HKG:2142) Revenues Pushing Shares 29% Lower
The HBM Holdings Limited (HKG:2142) share price has fared very poorly over the last month, falling by a substantial 29%. For any long-term shareholders, the last month ends a year to forget by lock
Simply Wall StApr 16 21:07 ET
Hebo Pharmaceutical-B (02142.HK) grants 8.38,000 share options and 3.105 million share awards
On April 3, 2024, Gelonghui Pharmaceutical-B (02142.HK) announced that on April 3, 2024, according to the share option plan and share award plan separately adopted by the company's shareholders on November 23, 2020, the company granted 8.310,000 share options and 3.105 million share awards to eligible participants, subject to acceptance by the grantor.
Gelonghui FinanceApr 3 07:06 ET
Hebo Pharmaceutical-B issued 1,713,500 shares under the share award program on April 2
Hebo Pharmaceutical-B (02142) announced that on April 2, 2024, it will issue 1,713,500 shares under the share award program.
新浪港股Apr 2 20:41 ET
HBM Holdings Returns to Profitability in 2023
HBM Holdings (HKG:2142) recorded a profit of $22.8 million in 2023, as opposed to a loss of $137.3 million in the previous year, according to a March. 28 filing with the Hong Kong bourse. Basic earnin
MT NewswiresApr 2 09:19 ET
No Data
No Data